260553-97-7

TM-25659 (50 mg/kg, i.p., every other day for 2 weeks) suppresses bone loss in vivo and decreases weight gain in an obesity model^[1].

TM-25659 has a favourable pharmacokinetic profile in rats. The plasma concentration of TM-25659 declines with an approximate t_1/2 of 7 or 10 h following i.v or p.o. administration respectively. The systemic clearance (CL) is 0.21 L×h^-1×kg^-1 and the volume of distribution at steady-state (1.91 L×h^-1×kg^-1) is larger than the volume of total body fluids^[1].